Shionogi starts pivotal Japanese trial of Akili’s ADHD app
pharmaphorum
AUGUST 2, 2022
“ADHD has a significant impact on children and their families in Asia, and caregivers and healthcare providers are looking for innovative non-drug treatment options,” said Takeki Uehara, head of drug development and regulatory science at Shionogi. Image by Gemma Moll from Pixabay .
Let's personalize your content